Patented product revenue share
20%
+17pp YoY
Patented products now contribute 20% of revenue vs 3% three years ago.
GSPCROPSCIENCE
Other
10 Feb 2026
GSP Crop Science Ltd — Q3 FY26
GSP Crop Science reported strong 9M FY26 results with revenue of ₹1,114 crore and EBITDA of ₹153 crore, up 32% YoY.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
GSP Crop Science reported strong 9M FY26 results with revenue of ₹1,114 crore and EBITDA of ₹153 crore, up 32% YoY. PAT stood at ₹75 crore (vs ₹59.6 crore last year) after a ₹4.5 crore exceptional item. Growth was driven by patented product portfolio (now 20% of revenue, up from 3% three years ago), robust B2B and B2C domestic verticals, and successful pass-through of raw material cost increases. Management guided for continued 20-25% revenue CAGR over three years, targeting 40-50% revenue from patented products. Key risk: prolonged Middle East conflict could disrupt raw material supply beyond current 45-day inventory cover, impacting margins if cost pass-through lags.
Key Numbers
Patents granted
102
+108 in pipeline
102 patents received, 108 in pipeline; 12 commercialized so far.
Technical plant utilization
70-75%
flat
Technical plants at Mandai and Ahmedabad run at 70-75% utilization; peak 90%.
Co-marketing partners
Multiple
flat
Partners include Rallis, Sumitomo, Mankind Agritech, Chambal Fertilizers.
Management Guidance
Revenue growth target of 20-25% CAGR over 3 years
Management expects to sustain or exceed historical growth rate by 5-7% annually, targeting 20-25% CAGR.
Management guidance growthPatented products to reach 40-50% of revenue in 3 years
Patented product revenue share to increase from current 20% to 40-50% over the next three years.
Management guidance revenueOne to two new patented product launches per year
Company plans to launch 1-2 new patented products annually, each requiring ~5 years for registration.
Management guidance growthBrazil subsidiary for patented product registrations
Subsidiary in Brazil established; registering patented products for export and potential local patenting.
Management guidance expansionKey Risks
Raw material supply disruption from Middle East conflict
Prolonged conflict could disrupt imports beyond current 45-day inventory cover, impacting production.
high · analyst_questionCost pass-through lag in B2C segment
Price increases in B2C take 2-3 months to implement, potentially squeezing margins if costs rise faster.
medium · management_commentarySlow product commercialization from patent pipeline
Only 12 of 102 patents commercialized; registration takes ~5 years, limiting near-term revenue impact.
medium · data_observationNotable Quotes
We have already received 102 patent in our basket and 108 patent is in our pipeline.
In the upcoming 3 years we see that almost 40 to 50% revenue will be coming from this kind of products.
We have started increasing our pricing on giving signals from 1st April wherein we are seeing the acceptance also coming from the market.
Frequently Asked Questions
What was GSP Crop Science's revenue in Q3 FY26?
GSP Crop Science reported revenue of ₹270 Cr in Q3 FY26, representing a — change compared to the same quarter last year.
What guidance did GSP Crop Science management give for FY27?
Revenue growth target of 20-25% CAGR over 3 years: Management expects to sustain or exceed historical growth rate by 5-7% annually, targeting 20-25% CAGR. Patented products to reach 40-50% of revenue in 3 years: Patented product revenue share to increase from current 20% to 40-50% over the next three years. One to two new patented product launches per year: Company plans to launch 1-2 new patented products annually, each requiring ~5 years for registration. Brazil subsidiary for patented product registrations: Subsidiary in Brazil established; registering patented products for export and potential local patenting.
What are the key risks for GSP Crop Science in FY27?
Key risks include Raw material supply disruption from Middle East conflict — Prolonged conflict could disrupt imports beyond current 45-day inventory cover, impacting production.; Cost pass-through lag in B2C segment — Price increases in B2C take 2-3 months to implement, potentially squeezing margins if costs rise faster.; Slow product commercialization from patent pipeline — Only 12 of 102 patents commercialized; registration takes ~5 years, limiting near-term revenue impact..
Did GSP Crop Science meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full GSP Crop Science Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.